Glaukos Corp(NYSE:GKOS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Company reported revenue of $28.56M. Analysts estimated a revenue of $24.45M. Earnings per share were $0.06. Analysts had estimated an EPS of $-0.04.
In a different note, Cantor Fitzgerald said it Initiates Coverage on Glaukos Corp, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Buy’ by the firm. On May 4, 2016, Roth Capital said it Maintains its rating on Glaukos Corp. In the research note, the firm Raises the price-target to $24.00 per share. The shares have been rated ‘Buy’ by the firm.
Glaukos Corp (GKOS) made into the market gainers list on Mondays trading session with the shares advancing 1.79% or 0.59 points. Due to strong positive momentum, the stock ended at $33.63, which is also near the day’s high of $33.65. The stock began the session at $33.04 and the volume stood at 5,06,928 shares. The 52-week high of the shares is $36.5 and the 52 week low is $14.25. The company has a current market capitalization of $1,111 M and it has 3,30,24,339 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 27, 2016, Richard L Harrison (Treasurer, CFO & Secretary) sold 10,000 shares at $35.01 per share price.Also, On Jul 13, 2016, Thomas William Burns (Chief Executive Officer) sold 162,254 shares at $30.03 per share price.On Jun 16, 2016, Chris M. Calcaterra (Chief Commercial Officer) sold 45,464 shares at $28.46 per share price, according to the Form-4 filing with the securities and exchange commission.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.